相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Patricia J. Simner et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients
Marco Falcone et al.
CLINICAL INFECTIOUS DISEASES (2021)
Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison to Disk Diffusion to Broth Microdilution
C. Paul Morris et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
Yoshinori Yamano
CLINICAL INFECTIOUS DISEASES (2019)
Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward molecularly targeted' therapy
Nadim G. El Chakhtoura et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis
Amber Martin et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Chromosomal Amplification of the blaOXA-58 Carbapenemase Gene in a Proteus mirabilis Clinical Isolate
Delphine Girlich et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)